Angelo E. Ruggiero

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 147 publications

Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.

Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.

Journal: Expert opinion on biological therapy

Published: April 01, 2026

Deucravacitinib in moderate-to-severe plaque psoriasis: a real-world study of effectiveness and safety in clinical practice.

Deucravacitinib in moderate-to-severe plaque psoriasis: a real-world study of effectiveness and safety in clinical practice.

Journal: Clinical and experimental dermatology

Published: March 27, 2026

Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.

Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.

Journal: Psoriasis (Auckland, N.Z.)

Published: March 23, 2025

Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study.

Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study.

Journal: Archives of dermatological research

Published: October 06, 2024

Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study.

Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study.

Journal: Clinical and experimental dermatology

Published: September 11, 2024

Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis.

Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis.

Journal: Expert opinion on drug safety

Published: August 12, 2024

The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis.

The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis.

Journal: Expert opinion on biological therapy

Published: July 22, 2024

Cutaneous Squamous Cell Carcinoma: From Diagnosis to Follow-Up.

Cutaneous Squamous Cell Carcinoma: From Diagnosis to Follow-Up.

Journal: Cancers

Published: July 04, 2024

Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation.

Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation.

Journal: Expert opinion on drug safety

Published: May 03, 2024

Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report.

Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report.

Journal: Clinical, cosmetic and investigational dermatology

Published: April 05, 2024

Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.

Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.

Journal: Journal of clinical medicine

Published: March 26, 2024

Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.

Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.

Journal: Clinical and experimental dermatology

Published: March 15, 2024

Showing 1-12 of 147

Last Updated: 09/26/2026